Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is poised to disrupt the field of immunotherapy with its innovative CD19 and CD22-targeted ARTEMIS T-cell therapies, providing a promising treatment option for patients with blood cancers and solid tumors. With the ongoing success of its STARLIGHT-1 study and strong commentary from management, the company is making strides in advancing its clinical program and has extended its operational runway with its recent capital raise. Despite its recent decline, the potential for future partnerships and market opportunities in the field of CAR-T therapy make Estrella Immunopharma a strong long-term investment with a conservative target price of $8.00.

Bears say

Estrella Immunopharma is a clinical-stage biopharmaceutical company with a negative outlook due to concerns about the success of their ARTEMIS T-cell therapy platform. The company's valuation is based on only a 30% probability of success and a 30% discount rate, indicating limited confidence in their potential. While they have entered Phase II with their EB103 treatment, there are concerns about its ability to address limitations of existing CAR-T therapies and the company's cash burn and potential future raises raise further concerns about their long-term prospects.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.